{'output': [['Exelixis Inc.', 'ORG', 'Announce', 'Amendment', 'CONCEPT'], ['Exelixis Inc.', 'ORG', 'Operate_In', 'Pharmaceutical Industry', 'SECTOR'], ['Amendment', 'CONCEPT', 'Relate_To', 'Protocol', 'CONCEPT'], ['Protocol', 'CONCEPT', 'Relate_To', 'Phase 1B Trial', 'CONCEPT'], ['Phase 1B Trial', 'CONCEPT', 'Relate_To', 'Cabozantinib', 'PRODUCT'], ['Cabozantinib', 'PRODUCT', 'Operate_In', 'Cancer Treatment', 'SECTOR'], ['Cabozantinib', 'PRODUCT', 'Combine_With', 'Atezolizumab', 'PRODUCT'], ['Atezolizumab', 'PRODUCT', 'Operate_In', 'Cancer Treatment', 'SECTOR'], ['Amendment', 'CONCEPT', 'Add', 'Four New Expansion Cohorts', 'CONCEPT'], ['Expansion Cohorts', 'CONCEPT', 'Include', 'Patients With NSCLC', 'CONCEPT'], ['Expansion Cohorts', 'CONCEPT', 'Include', 'Patients With CRPC', 'CONCEPT']]}